Advanced Search
XU Hairong, LI Yuan, SHAN Huachao, YU Feng, NIU Xiaohui. Epidemiological and Clinical Characteristics of Fibrous Dysplasia of Bone[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 408-411. DOI: 10.3971/j.issn.1000-8578.2022.22.0231
Citation: XU Hairong, LI Yuan, SHAN Huachao, YU Feng, NIU Xiaohui. Epidemiological and Clinical Characteristics of Fibrous Dysplasia of Bone[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 408-411. DOI: 10.3971/j.issn.1000-8578.2022.22.0231

Epidemiological and Clinical Characteristics of Fibrous Dysplasia of Bone

More Information
  • Corresponding author:

    NIU Xiaohui, E-mail: niuxiaohui@263.net

  • Received Date: March 09, 2022
  • Revised Date: March 30, 2022
  • Available Online: January 12, 2024
  • Objective 

    To describe the epidemiological and clinical characteristics of fibrous dysplasia of bone admitted to a single center in the past 30 years.

    Methods 

    We analyzed the clinical features of 744 patients with bone fibrous dysplasia diagnosed by pathology, including age, gender, disease location, monostotic or polyostotic lesions, pathological fracture and malignant transformation.

    Results 

    There were 1183 lesions in 744 patients. The mean age at admission was 31.1±13.5 years old. The ratio of male to female was close to 1:1. The most common site was the lower extremities (916(77.4%)), followed by the upper extremities (106(9.0%)). The most common sites of lower extremities were the femur (645(54.5%)) and the tibia (224(18.9%)). Polyostotic cases accounted for 25.4%, and monostotic cases accounted for 74.6%. Pathological fracture occurred in 163 (13.8%) patients. There were 6 (0.8%) patients with malignant transformation. The mean age was 40.5 years old. The mean time of malignant transformation was 7.7 years.

    Conclusion 

    Fibrous dysplasia of bone is a rare group of benign bone tumors, with typical epidemiological and clinical features.

  • Competing interests: The authors declare that they have no competing interests.

  • [1]
    Lichtenstein L. Polyostotic fibrous dysplasia[J]. Arc Surg, 1938, 36(5): 874-898. doi: 10.1001/archsurg.1938.01190230153012
    [2]
    Campanacci M. Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology and Treatment[J]. Bone Joint Surg, 1999: 435-461.
    [3]
    Kancherla NR, Eppakayala S, Nagesh C, et al. Functional outcome in surgical fixation of fibrous dysplasia of proximal femur[J]. Int J Res Orthop, 2022, 8(2): 138-142. doi: 10.18203/issn.2455-4510.IntJResOrthop20220598
    [4]
    Gorgolini G, Caterini A, Nicotra L, et al. Surgical treatment of femoral deformities in polyostotic fibrous dysplasia and McCune-Albright syndrome: A literature review[J]. World J Orthop, 2022, 13(3): 329-338. doi: 10.5312/wjo.v13.i3.329
    [5]
    Vyas A, Godara A, Kumar N, et al. Fibrous Dysplasia of Proximal Femur: A Case Report of Treatment With Single-Stage Valgus Osteotomy With Dynamic Hip Screw and Fibular Strut Graft[J]. Cureus, 2022, 14(1): e21496.
    [6]
    Marie PJ, Pollak C de, Chanson P, et al. Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia[J]. Am J Pathol, 1997, 150(3): 1059-1069.
    [7]
    Geels RES, Meier ME, Saikali A, et al. Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors[J]. J Bone Miner Res, 2022, 37(2): 236-243. doi: 10.1002/jbmr.4463
    [8]
    Diyora B, Dey S, Dubey A, et al. Cranial fibrous dysplasia: An institutional experience and review of the literature[J]. Surg Neurol Int, 2022, 13: 66. doi: 10.25259/SNI_1218_2021
    [9]
    Benhamou J, Gensburger D, Messiaen C, et al. Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study[J]. J Bone Miner Res, 2016, 31(12): 2167-2172. doi: 10.1002/jbmr.2894
    [10]
    Cheng J, Wang Y, Yu H, et al. An epidemiological and clinical analysis of craniomaxillofacial fibrous dysplasia in a Chinese population[J]. Orphanet J Rare Dis, 2012, 7: 80. doi: 10.1186/1750-1172-7-80
    [11]
    MacDonald-Jankowski D. Fibrous dysplasia: a systematic review[J]. Dentomaxillofac Radiol, 2009, 38(4): 196-215. doi: 10.1259/dmfr/16645318
    [12]
    Leet AI, Boyce AM, Ibrahim KA, et al. Bone-Grafting in Polyostotic Fibrous Dysplasia[J]. J Bone Joint Surg Am, 2016, 98(3): 211-219. doi: 10.2106/JBJS.O.00547
    [13]
    Majoor BCJ, Papapoulos SE, Dijkstra PD, et al. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates[J]. J Clin Endocrinol Metab, 2019, 104(12): 6069-6078. doi: 10.1210/jc.2018-02543
    [14]
    Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia[J]. J Bone Miner Res, 2012, 27(7): 1462-1470. doi: 10.1002/jbmr.1603
    [15]
    MM B, Shahidul I, Tanvir A. Tibial fibrous dysplasia in children treated by Ilizarov Technique-A review of treatment options[J]. MOJ Orthopedics Rheumatol, 2021, 13(2): 26-29. doi: 10.15406/mojor.2021.13.00542
    [16]
    Florez H, Peris P, Guañabens N. Fibrous dysplasia. Clinical review and therapeutic management[J]. Med Clin (Barc), 2016, 147(12): 547-553. doi: 10.1016/j.medcli.2016.07.030
    [17]
    Li W, Huang X, Ye Z, et al. Valgus osteotomy in combination with dynamic hip screw fixation for fibrous dysplasia with shepherd' s crook deformity[J]. Arch Orthop Trauma Surg, 2013, 133(2): 147-152. doi: 10.1007/s00402-012-1633-1
    [18]
    Yang L, Jing Y, Hong D, et al. Valgus osteotomy combined with intramedullary nail for Shepherd's crook deformity in fibrous dysplasia: 14 femurs with a minimum of 4 years follow-up[J]. Arch Orthop Trauma Surg, 2010, 130(4): 497-502. doi: 10.1007/s00402-009-0943-4
    [19]
    Breck LW. Treatment of Fibrous Dysplasia of Bone by Total Femoral Plating and Hip Nailing A Case Report[J]. Clin Orthop Relat Res, 1972, 82: 82-83.
    [20]
    Connolly JF. Shepherd's Crook Deformities of Polyostotic Fibrous Dysplasia Treated by Osteotomy and Zickel Nail Fixation[J]. Clin Orthop Relat Res, 1977, 123: 22-24.
    [21]
    DiMeglio LA. Bisphosphonate therapy for fibrous dysplasia[J]. Pediatr Endocrinol Rev, 2007, 4 Suppl 4: 440-445.
    [22]
    DiCaprio MR, Enneking WF. Fibrous Dysplasia. Pathophysiology, evaluation, and treatment[J]. J Bone Joint Surg, 2005, 87(8): 1848-1864.
    [23]
    Benhamou J, Gensburger D, Chapurlat R. Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment[J]. Joint Bone Spine, 2014, 81(6): 549-550. doi: 10.1016/j.jbspin.2014.04.013
    [24]
    Hampton MJ, Weston-Simmons S, Giles SN, et al. Deformity Correction, Surgical Stabilisation and Limb Length Equalisation in Patients with Fibrous Dysplasia: A 20-year Experience[J]. Strategies Trauma Limb Reconstr, 2021, 16(1): 41-45. doi: 10.5005/jp-journals-10080-1523
    [25]
    Chen WJ, Chen WM, Chiang CC, et al. Shepherd's Crook Deformity of Polyostotic Fibrous Dysplasia Treated with Corrective Osteotomy and Dynamic Hip Screw[J]. J Chin Med Assoc, 2005, 68(7): 343-346. doi: 10.1016/S1726-4901(09)70173-X
    [26]
    Yabut Jr SM, Kenan S, Sissons HA, et al. Malignant transformation of fibrous dysplasia. A case report and review of the literature[J]. Clin Orthop Relat Res, 1988, 228: 281-289.
    [27]
    Ruggieri P, Sim FH, Bond JR, et al. Malignancies in fibrous dysplasia[J]. Cancer, 1994, 73(5): 1411-1424. doi: 10.1002/1097-0142(19940301)73:5<1411::AID-CNCR2820730516>3.0.CO;2-T

Catalog

    Figures(2)  /  Tables(1)

    Article views (1723) PDF downloads (1024) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return